207 related articles for article (PubMed ID: 36166443)
21. Healthcare resource utilization prior to suicide death or suicide attempt in patients with major depressive disorder-A Danish registry-based cohort study.
Jensen KJ; Osler M; Bødker N; Riise J; Petersen J
Suicide Life Threat Behav; 2023 Jun; 53(3):399-414. PubMed ID: 36825304
[TBL] [Abstract][Full Text] [Related]
22. The prevalence and economic burden of treatment-resistant depression in Thailand.
Prasartpornsirichoke J; Pityaratstian N; Poolvoralaks C; Sirinimnualkul N; Ormtavesub T; Hiranwattana N; Phonsit S; Rungnirundorn T
BMC Public Health; 2023 Aug; 23(1):1541. PubMed ID: 37573321
[TBL] [Abstract][Full Text] [Related]
23. US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study.
Pilon D; Szukis H; Joshi K; Singer D; Sheehan JJ; Wu JW; Lefebvre P; Greenberg P
Pharmacoecon Open; 2020 Mar; 4(1):119-131. PubMed ID: 31254275
[TBL] [Abstract][Full Text] [Related]
24. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans.
Joshi K; Pilon D; Shah A; Holiday C; Karkare S; Zhdanava M
J Med Econ; 2023; 26(1):422-429. PubMed ID: 36924214
[TBL] [Abstract][Full Text] [Related]
25. Economic impact of treatment-resistant depression: A retrospective observational study.
Pérez-Sola V; Roca M; Alonso J; Gabilondo A; Hernando T; Sicras-Mainar A; Sicras-Navarro A; Herrera B; Vieta E
J Affect Disord; 2021 Dec; 295():578-586. PubMed ID: 34509073
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
[TBL] [Abstract][Full Text] [Related]
27. Treatment-resistant depression increases health costs and resource utilization.
Lepine BA; Moreno RA; Campos RN; Couttolenc BF
Braz J Psychiatry; 2012 Dec; 34(4):379-88. PubMed ID: 23429808
[TBL] [Abstract][Full Text] [Related]
28. Descriptive analysis of the economic burden of treatment resistance in a major depressive episode.
Cai Q; Sheehan JJ; Wu B; Alphs L; Connolly N; Benson C
Curr Med Res Opin; 2020 Feb; 36(2):329-335. PubMed ID: 31540559
[No Abstract] [Full Text] [Related]
29. Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization.
McIntyre RS; Millson B; Power GS
J Affect Disord; 2020 Dec; 277():30-38. PubMed ID: 32791390
[TBL] [Abstract][Full Text] [Related]
30. An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression.
Wu B; Cai Q; Sheehan JJ; Benson C; Connolly N; Alphs L
PLoS One; 2019; 14(8):e0220763. PubMed ID: 31393922
[TBL] [Abstract][Full Text] [Related]
31. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database.
Kubitz N; Mehra M; Potluri RC; Garg N; Cossrow N
PLoS One; 2013; 8(10):e76882. PubMed ID: 24204694
[TBL] [Abstract][Full Text] [Related]
32. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K
J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075
[TBL] [Abstract][Full Text] [Related]
33. Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland - a matched cohort study.
Taipale H; Lähteenvuo M; Tanskanen A; Huoponen S; Rannanpää S; Tiihonen J
BMC Psychiatry; 2022 Jul; 22(1):484. PubMed ID: 35854248
[TBL] [Abstract][Full Text] [Related]
34. Cause-specific life years lost in individuals with treatment-resistant depression: A Danish nationwide register-based cohort study.
Madsen KB; Plana-Ripoll O; Musliner KL; Debost JP; Petersen LV; Munk-Olsen T
J Affect Disord; 2021 Feb; 280(Pt A):250-257. PubMed ID: 33220561
[TBL] [Abstract][Full Text] [Related]
35. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
[TBL] [Abstract][Full Text] [Related]
36. Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy.
Pilon D; Karkare S; Zhdanava M; Sheehan JJ; Côté-Sergent A; Shah A; Lopena OJ; Lefebvre P; Joshi K; Citrome L
J Med Econ; 2021; 24(1):1299-1308. PubMed ID: 34763603
[TBL] [Abstract][Full Text] [Related]
37. Incidence of, Risk Factors for, and Changes Over Time in Treatment-Resistant Depression in Denmark: A Register-Based Cohort Study.
Gronemann FH; Jorgensen MB; Nordentoft M; Andersen PK; Osler M
J Clin Psychiatry; 2018 May; 79(4):. PubMed ID: 29873959
[TBL] [Abstract][Full Text] [Related]
38. The economic impact of depression: resistance or severity?
Fostick L; Silberman A; Beckman M; Spivak B; Amital D
Eur Neuropsychopharmacol; 2010 Oct; 20(10):671-5. PubMed ID: 20624674
[TBL] [Abstract][Full Text] [Related]
39. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study.
Denee T; Kerr C; Ming T; Wood R; Tritton T; Middleton-Dalby C; Massey O; Desai M
J Psychiatr Res; 2021 Jul; 139():172-178. PubMed ID: 34077893
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression.
Zhdanava M; Karkare S; Pilon D; Joshi K; Rossi C; Morrison L; Sheehan J; Lefebvre P; Lopena O; Citrome L
Adv Ther; 2021 Sep; 38(9):4900-4916. PubMed ID: 34368919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
